Eton Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon, everyone, and welcome to the last day of our 24th Annual Global Investment Conference. My name is Jorge King, Equity Research Associate at H.C. Wainwright, and it's my pleasure to introduce our next speaker from Eton Pharmaceuticals. Please welcome, CEO, Sean Brynjelsen.
Thank you, Jorge. Thank you, everyone, for tuning in today. I'm looking forward to sharing a little bit about the Eton story. The company was founded with a simple promise, and that was we're reimagining molecules to advance medicine. What that means is that we looked for low-hanging fruit in the market where there was some value to be added either through a formulation, a new indication, or perhaps enhanced stability. And so the formation of the company five years ago focused on that.
As we evolved, and we looked, and we obtained a number of approvals over the years, we've refocused the company to be a rare disease company. Many of our non-core assets are now royalty
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |